Mr. President,
There is an opportunity to improve the quest for cures for many diseases, including cancers, by increasing the instrumentation budget for advanced detection of physical properties of the genome, such as being able to view the conformal shape of DNA in live cells as it twists and turns, winds and unwinds, achieving 5500:1 rates of compression in size, knowing when to unwind and transcribe, photon and EMF emission by DNA in cells in vivo and in vitro, which we have no way to measure today; etc. Included in this
proposed initiative should be the involvement of more physicists to aid molecular biologists in their interpretation of the state of activity, including quantum mechanics, at work in the nanoworld of live cells.
We cannot see into the nucleus of live cells very effectively, and most of our understanding of DNA, its role in cells, and cellular signalling, is deduced from chemical analysis and imputation. Not from direct observation and measurement. Advances in many technologies, including nanotechnology, neutron imaging, microscopy, SEM and AFM, X-Ray crystallography, and more, are widening our ability to see.
Only two years ago the NIH began funding instrumentation to facilitate sensing at the nano levels needed to really understand the processes of cellular biology.
Complicating this quest is the lack of much coalescence among fields of science. Few molecular biologists understand advanced physics, photonics, Van der Waals forces, et al. And the reverse is also true, few physicists are knowledgeable, in depth, about what goes on in cells, at the level of understanding the potential role of histones, microtubules, cellular signalling, and the complex, interrelated activities of the cells which make up our bodies and determine our health, longevity, aging and survival.
We are benefitted by the significant investments into nano/bio technologies being funded through NIH, NSF, DARPA/DOD. An increase, modest on the scale of the overall budget, with a research mandate encouraging exploring these new areas of potential discovery, can yield enormous benefits in developing diagnostics, and as a result of that, therapeutics, to tackle the many diseases afflicting humanity, and the current enormous cost of treating these diseases.
Mike Weiner
CEO, Biophan Technologies, Inc.